Home › Compare › ITFRF vs ABBV
ITFRF yields 5.03% · ABBV yields 3.06%● Live data
📍 ITFRF pulled ahead of the other in Year 1
Combined, ITFRF + ABBV cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of ITFRF + ABBV for your $10,000?
ITFOR Inc. provides support services for the implementation of information technology in Japan. It develops solutions comprising consulting, system configuration, customer specific solution development, operation, and management for network security. The company also offers financial solution systems, such as credit collection, loan assessment management, scoring, collecting, tele-marketing, and local governments systems; CTI systems that offer call-center productivity enhancements; consultation and installation of open platform for retail service customers; and e-commerce systems. In addition, it provides network systems, including corporate infrastructure network, backbone network consultation and design, IP services, edge solutions for telecom carriers, network security solutions, and personal information management; and professional and consultation services, as well as customer services. The company was formerly known as CJK Co. Ltd. and changed its name to ITFOR Inc. in 2000. ITFOR Inc. was founded in 1972 and is headquartered in Tokyo, Japan.
Full ITFRF Calculator →AbbVie Inc. discovers, develops, manufactures, and sells pharmaceuticals in the worldwide. The company offers HUMIRA, a therapy administered as an injection for autoimmune and intestinal Behçet's diseases; SKYRIZI to treat moderate to severe plaque psoriasis in adults; RINVOQ, a JAK inhibitor for the treatment of moderate to severe active rheumatoid arthritis in adult patients; IMBRUVICA to treat adult patients with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), and VENCLEXTA, a BCL-2 inhibitor used to treat adults with CLL or SLL; and MAVYRET to treat patients with chronic HCV genotype 1-6 infection. It also provides CREON, a pancreatic enzyme therapy for exocrine pancreatic insufficiency; Synthroid used in the treatment of hypothyroidism; Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation; Lupron for the palliative treatment of advanced prostate cancer, endometriosis and central precocious puberty, and patients with anemia caused by uterine fibroids; and Botox therapeutic. In addition, the company offers ORILISSA, a nonpeptide small molecule gonadotropin-releasing hormone antagonist for women with moderate to severe endometriosis pain; Duopa and Duodopa, a levodopa-carbidopa intestinal gel to treat Parkinson's disease; Lumigan/Ganfort, a bimatoprost ophthalmic solution for the reduction of elevated intraocular pressure (IOP) in patients with open angle glaucoma (OAG) or ocular hypertension; Ubrelvy to treat migraine with or without aura in adults; Alphagan/ Combigan, an alpha-adrenergic receptor agonist for the reduction of IOP in patients with OAG; and Restasis, a calcineurin inhibitor immunosuppressant to increase tear production, as well as other eye care products. AbbVie Inc. has a research collaboration with Dragonfly Therapeutics, Inc. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Full ABBV Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.